Liver Transplant clinical trials

Explore recruiting liver transplant clinical trials.

Recruiting liver transplant studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Liver Transplant trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

NEurotrophins MImetic compound for modulation of ischemia/reperfusion damage in Liver transplantation with Extended criteria Donors, a phase I/II explorative, open label, controlled, randomized study

Italy

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A single-arm, open-label, multi-centre, phase I/II study evaluating the safety and clinical activity of QEL-001, an autologous CAR T regulatory cell treatment targeting HLA-A2, in HLA-A2/ A28neg patients that have received an HLA-A2pos liver transplant.

Belgium, Spain

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Odevixibat (A4250) in Children with Biliary Atresia Who Have Undergone a Kasai Hepatoportoenterostomy (BOLD)

Hungary, Belgium, France, Spain, Poland, Germany +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat (A4250) in Children with Biliary Atresia (BOLD-EXT)

Spain, Italy, Germany, Poland, Hungary, France +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Efficacy and safety of pharmacological therapy of obesity in liver transplant candidates

Czechia

Therapeutic use (Phase IV) EU CTIS Study details

A 60 month, single-arm, proof-of-concept study to induce allogeneic tolerance in deceased donor liver transplant recipients using siplizumab, an anti-CD2 antibody in combination with cyclophosphamide and splenectomy.

Sweden

Therapeutic exploratory (Phase II) EU CTIS Study details

Liver Transplant trials by city

Liver Transplant in Toronto Liver Transplant in Vancouver Liver Transplant in Montreal Liver Transplant in Calgary Liver Transplant in Edmonton Liver Transplant in Ottawa Liver Transplant in Winnipeg Liver Transplant in Quebec City Liver Transplant in Hamilton Liver Transplant in Kitchener Liver Transplant in London Liver Transplant in Halifax Liver Transplant in New York Liver Transplant in Los Angeles Liver Transplant in Chicago Liver Transplant in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease